U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Medical Devices
  3. Device Advice: Comprehensive Regulatory Assistance
  4. Guidance Documents (Medical Devices and Radiation-Emitting Products)
  5. Quality Control Material for Cystic Fibrosis Nucleic Acid Assays - Class II Special Controls Guidance for Industry and FDA Staff
  1. Guidance Documents (Medical Devices and Radiation-Emitting Products)

Quality Control Material for Cystic Fibrosis Nucleic Acid Assays - Class II Special Controls Guidance for Industry and FDA Staff

Read the Special Controls Document

Issue Date: 01/20/2007

Issued By: Office of Medical Products and Tobacco, Center for Devices and Radiological Health, Office of In Vitro Diagnostic Device Evaluation and Safety Division of Immunology and Hematology Devices

This guidance document was developed as a special controls guidance to support the classification of quality control material for cystic fibrosis nucleic acid assays into class II (special controls). A quality control material for cystic fibrosis nucleic acid assays is a device intended to help monitor reliability of a test system by detecting analytical deviations such as those that may arise from reagent or instrument variation in genetic testing. This type of device includes recombinant, synthetic, and cell line-based DNA controls.

Back to Top